Description

L-Threo-Ritalinic Acid CAS NO 129389-68-0 is a key chiral intermediate and a major metabolite of the central nervous system stimulant methylphenidate. This high-purity compound is essential for pharmaceutical research and development, particularly in the study of drug metabolism, pharmacokinetics, and the synthesis of novel therapeutic agents. It is primarily sought by pharmaceutical manufacturers, analytical laboratories, and research institutions engaged in neuroscience, pharmacology, and the development of treatments for attention deficit hyperactivity disorder (ADHD).

Application

• Pharmaceutical Reference Standard: Used as a certified reference material (CRM) for the quantitative and qualitative analysis of methylphenidate and its metabolites in biological matrices.
• Metabolite Studies: Critical for in vitro and in vivo studies investigating the metabolic pathways, bioavailability, and clearance of methylphenidate-based therapeutics.
• Active Pharmaceutical Ingredient (API) Synthesis: Serves as a crucial chiral building block in the synthesis and process development of advanced pharmaceutical compounds.
• Forensic and Clinical Toxicology: Employed as an analytical standard in forensic labs and hospitals for accurate drug testing and monitoring in compliance with regulatory guidelines.
• Pharmacological Research: Utilized in research to understand the stereospecific activity, receptor binding, and side-effect profiles associated with methylphenidate enantiomers.
• Method Development and Validation: Essential for developing and validating robust HPLC, LC-MS, and GC-MS analytical methods in quality control and research settings.

Basic Information

Product Name	L-Threo-Ritalinic Acid
CAS No.	129389-68-0
Molecular Formula	C14H19NO2
Molecular Weight	233.31 g/mol
Synonyms	(2R,2'R)-2-Phenyl-2-(2-piperidin-2-yl)acetic acid; (-)-threo-Ritalinic acid; L-threo-Methylphenidate acid; L-threo-α-Phenyl-α-(2-piperidyl)acetic acid; R,R-Methylphenidate metabolite; d-threo-Ritalinic acid; Focalin acid metabolite; Dexmethylphenidate acid metabolite
EINECS	Contact for details

Quality Control

Our L-Threo-Ritalinic Acid is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including chiral purity verification by HPLC, to ensure it meets the stringent requirements for pharmaceutical research and reference standard applications. A detailed Certificate of Analysis (COA) providing batch-specific results for identity, purity, and impurities is supplied with every order.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept in a desiccated environment to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (HPLC)	≥99.0% (L-Threo isomer)
Related Substances (HPLC)	Total impurities ≤2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.